Viewing StudyNCT06405230

Home Icon Home Search Icon Search Alerts Icon Stocks Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Main Search All Studies All Organizations Report Bug
View Study With Definitions
Ignite Creation Date: 2024-05-11 @ 8:31 AM
Last Modification Date: 2024-10-26 @ 3:29 PM
Study NCT ID: NCT06405230
Status: NOT_YET_RECRUITING
Last Update Posted: 2024-05-08
First Post: 2024-04-18
Brief Title: Evaluation of Programmed Death Ligand 1 PDL1 Response to Treatment in Patient-derived Organoids and Immune-marker Positron Emission Tomography PET Scanning in Non-small Cell Lung Cancer NSCLC
Sponsor: GlaxoSmithKline
Organization: GlaxoSmithKline
Overview Dates Organization Conditions Design Enrollment Locations Outcomes

Conditions & Keywords Data

Conditions:
Name
Lung Cancer Non-Small Cell
Keywords:
Name View
Non-small cell lung cancer View
Pembrolizumab View
Dostarlimab View
Platinum-based chemotherapy doublet View
Programmed death ligand 1 View
Positron emission tomography View
Organoids View
Artificial intelligence View
Machine learning View